Jenny Rooke (Genoa Ventures)
April 22, 2021 07:32 AM EDTUpdated 08:12 AM
People
Financing

Ear­ly Zymer­gen in­vestor Jen­ny Rooke re­flects on 'chimeras' in biotech, what it takes to spot a $500M gem

Kyle Blankenship

When Jen­ny Rooke first heard of Zymer­gen back in 2014, she knew she was look­ing at some­thing dif­fer­ent and ex­cit­ing. The Emeryville, CA biotech held …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump’s sci­ence crack­down hits rare dis­ease re­search: ‘We need to sit down with Elon Musk’

At least sev­en drug­mak­ers say they will par­tic­i­pate in round two of IRA ne­go­ti­a­tions 

Ex­clu­sive: In­fec­tious dis­ease doc­tors con­sid­er 'mi­ni-ACIP' if RFK erodes CDC vac­cine pan­el

Ab­b­Vie fi­nal­ly en­ters obe­si­ty race with $350M up­front for Gubra’s amylin

Lil­ly joins mol­e­c­u­lar glue field with Mag­net deal worth up to $1.25B

sponsored

The per­fect storm: Why every­thing is in place for 2025 to be the year of GxP AI

A service from the Financial Times